---
document_datetime: 2025-12-29 11:14:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rotateq.html
document_name: rotateq.html
version: success
processing_time: 0.1238683
conversion_datetime: 2025-12-30 01:35:33.067061
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# RotaTeq

[RSS](/en/individual-human-medicine.xml/66341)

##### Authorised

This medicine is authorised for use in the European Union

rotavirus vaccine, live Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on RotaTeq](#news-on)
- [More information on RotaTeq](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for RotaTeq. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for RotaTeq.

Expand section

Collapse section

## What is RotaTeq?

RotaTeq is a vaccine that is taken by mouth. It is available as a solution in a single-dose tube. It contains five live rotavirus strains, each carrying a different antigen (G1, G2, G3, G4 and P1[8]).

## What is RotaTeq used for?

RotaTeq is used in babies from 6 to 32 weeks of age to protect against gastroenteritis (diarrhoea and vomiting) caused by rotavirus infections. RotaTeq is given according to official recommendations.

The vaccine can only be obtained with a prescription.

## How is RotaTeq used?

RotaTeq is given as three doses, with at least four weeks between each dose. The contents of the tube of RotaTeq are given directly into the baby's mouth. The first dose is given when the baby is between 6 and 12 weeks of age. It is recommended that the last dose be given to the child by the age of 20 to 22 weeks. If necessary it may be given up to the age of 32 weeks. RotaTeq can be given at the same time as other vaccinations (except the oral polio vaccine, when a two-week interval is needed between the two vaccines).

RotaTeq can be given to premature babies, as long as the pregnancy lasted at least 25 weeks. The first dose should be given six weeks after birth at the earliest.

## How does RotaTeq work?

There are various types of rotaviruses that cause gastroenteritis. They vary in that they may carry different antigens. An antigen is a specific structure that the body can recognise as 'foreign' and against which the body can make an antibody, a special protein that can neutralise or destroy the antigen. RotaTeq contains viruses that carry the antigens for some of the most commonly occurring types of rotaviruses. When a baby is given the vaccine, the immune system (the system that fights diseases) makes antibodies against these antigens, which help prevent infections caused by rotaviruses that occur naturally and carry the same or very similar antigens.

## How has RotaTeq been studied?

Overall, the studies of RotaTeq involved over 72,000 babies, including about 2,000 premature babies. About half of the babies received RotaTeq, and the others received placebo (a dummy vaccine). The main measure of effectiveness, which was studied in 6,000 babies, was the number of babies who developed rotavirus gastroenteritis during the following rotavirus season (the time of the year when rotaviruses are known to circulate and cause infection, generally during the cooler months in winter to early spring).

## What benefit has RotaTeq shown during the studies?

The number of cases of rotavirus gastroenteritis due to viruses with the same antigens as in the vaccine decreased following vaccination with RotaTeq. Among the almost 6,000 babies in whom the main measure of effectiveness was studied, 82 of the babies vaccinated with RotaTeq developed rotavirus gastroenteritis (one with severe gastroenteritis) compared with 315 of the babies who received placebo (51 severe cases). The study also showed that there were fewer hospital admissions or visits to emergency clinics for rotavirus gastroenteritis in babies vaccinated with RotaTeq.

## What is the risk associated with RotaTeq?

The most common side effects with RotaTeq (seen in more than 1 patient in 10) are pyrexia (fever), diarrhoea and vomiting. Very rarely (seen in less than 1 patient in 10,000), a serious condition called intussusception (in which part of the bowel becomes enfolded within another part of the bowel, leading to a blockage) has been reported after the use of rotavirus vaccines. For the full list of all side effects reported with RotaTeq, see the package leaflet.

RotaTeq must not be used in babies who are hypersensitive (allergic) to the active substance or any of the other ingredients, or who showed signs of allergy after receiving a dose of RotaTeq or another vaccine against rotavirus in the past. RotaTeq must not be given to babies who have had intussusception in the past or who have problems with their bowel that could put them at risk of intussusception. It must also not be used in babies whose immune system is weakened. Vaccination with RotaTeq should be postponed in babies who have a sudden high fever, diarrhoea or vomiting.

RotaTeq should never be injected under any circumstances.

## Why has RotaTeq been approved?

The CHMP decided that RotaTeq's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of RotaTeq?

A risk management plan has been developed to ensure that RotaTeq is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for RotaTeq, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about RotaTeq

The European Commission granted a marketing authorisation valid throughout the European Union for RotaTeq on 27 June 2006.

For more information about treatment with RotaTeq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

RotaTeq : EPAR - Summary for the public

English (EN) (82.57 KB - PDF)

**First published:** 03/06/2008

**Last updated:** 01/03/2016

[View](/en/documents/overview/rotateq-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-601)

български (BG) (108.24 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/bg/documents/overview/rotateq-epar-summary-public_bg.pdf)

español (ES) (81.65 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/es/documents/overview/rotateq-epar-summary-public_es.pdf)

čeština (CS) (108.62 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/cs/documents/overview/rotateq-epar-summary-public_cs.pdf)

dansk (DA) (81.08 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/da/documents/overview/rotateq-epar-summary-public_da.pdf)

Deutsch (DE) (83.05 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/de/documents/overview/rotateq-epar-summary-public_de.pdf)

eesti keel (ET) (80.55 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/et/documents/overview/rotateq-epar-summary-public_et.pdf)

ελληνικά (EL) (111.71 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/el/documents/overview/rotateq-epar-summary-public_el.pdf)

français (FR) (82.55 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/fr/documents/overview/rotateq-epar-summary-public_fr.pdf)

hrvatski (HR) (103.91 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/hr/documents/overview/rotateq-epar-summary-public_hr.pdf)

italiano (IT) (81.19 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/it/documents/overview/rotateq-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.76 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/lv/documents/overview/rotateq-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (105.48 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/lt/documents/overview/rotateq-epar-summary-public_lt.pdf)

magyar (HU) (104.35 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/hu/documents/overview/rotateq-epar-summary-public_hu.pdf)

Malti (MT) (108.75 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/mt/documents/overview/rotateq-epar-summary-public_mt.pdf)

Nederlands (NL) (81.25 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/nl/documents/overview/rotateq-epar-summary-public_nl.pdf)

polski (PL) (107.52 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/pl/documents/overview/rotateq-epar-summary-public_pl.pdf)

português (PT) (81.64 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/pt/documents/overview/rotateq-epar-summary-public_pt.pdf)

română (RO) (104.78 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/ro/documents/overview/rotateq-epar-summary-public_ro.pdf)

slovenčina (SK) (108.72 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/sk/documents/overview/rotateq-epar-summary-public_sk.pdf)

slovenščina (SL) (102.73 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/sl/documents/overview/rotateq-epar-summary-public_sl.pdf)

Suomi (FI) (80.59 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/fi/documents/overview/rotateq-epar-summary-public_fi.pdf)

svenska (SV) (80.98 KB - PDF)

**First published:**

03/06/2008

**Last updated:**

01/03/2016

[View](/sv/documents/overview/rotateq-epar-summary-public_sv.pdf)

RotaTeq : EPAR - Risk-management-plan summary

English (EN) (82.25 KB - PDF)

**First published:** 04/06/2021

[View](/en/documents/rmp-summary/rotateq-epar-risk-management-plan-summary_en.pdf)

## Product information

RotaTeq : EPAR - Product Information

English (EN) (269.84 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 18/12/2025

[View](/en/documents/product-information/rotateq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-66)

български (BG) (263.86 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/bg/documents/product-information/rotateq-epar-product-information_bg.pdf)

español (ES) (281.6 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/es/documents/product-information/rotateq-epar-product-information_es.pdf)

čeština (CS) (300.25 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/cs/documents/product-information/rotateq-epar-product-information_cs.pdf)

dansk (DA) (279.44 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/da/documents/product-information/rotateq-epar-product-information_da.pdf)

Deutsch (DE) (300.57 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/de/documents/product-information/rotateq-epar-product-information_de.pdf)

eesti keel (ET) (280.36 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/et/documents/product-information/rotateq-epar-product-information_et.pdf)

ελληνικά (EL) (274.5 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/el/documents/product-information/rotateq-epar-product-information_el.pdf)

français (FR) (313.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/fr/documents/product-information/rotateq-epar-product-information_fr.pdf)

hrvatski (HR) (331.86 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/hr/documents/product-information/rotateq-epar-product-information_hr.pdf)

íslenska (IS) (288.57 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/is/documents/product-information/rotateq-epar-product-information_is.pdf)

italiano (IT) (303.68 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/it/documents/product-information/rotateq-epar-product-information_it.pdf)

latviešu valoda (LV) (269.18 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/lv/documents/product-information/rotateq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (279.08 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/lt/documents/product-information/rotateq-epar-product-information_lt.pdf)

magyar (HU) (308.83 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/hu/documents/product-information/rotateq-epar-product-information_hu.pdf)

Malti (MT) (304.44 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/mt/documents/product-information/rotateq-epar-product-information_mt.pdf)

Nederlands (NL) (295.97 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/nl/documents/product-information/rotateq-epar-product-information_nl.pdf)

norsk (NO) (274.98 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/no/documents/product-information/rotateq-epar-product-information_no.pdf)

polski (PL) (304.13 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/pl/documents/product-information/rotateq-epar-product-information_pl.pdf)

português (PT) (294.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/pt/documents/product-information/rotateq-epar-product-information_pt.pdf)

română (RO) (301.76 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/ro/documents/product-information/rotateq-epar-product-information_ro.pdf)

slovenčina (SK) (293.37 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/sk/documents/product-information/rotateq-epar-product-information_sk.pdf)

slovenščina (SL) (284.25 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/sl/documents/product-information/rotateq-epar-product-information_sl.pdf)

Suomi (FI) (280.04 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/fi/documents/product-information/rotateq-epar-product-information_fi.pdf)

svenska (SV) (278.84 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

18/12/2025

[View](/sv/documents/product-information/rotateq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000301699 11/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

RotaTeq : EPAR - All Authorised presentations

English (EN) (31.83 KB - PDF)

**First published:** 21/09/2006

**Last updated:** 21/09/2006

[View](/en/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-178)

български (BG) (92.77 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/bg/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.56 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/es/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (86.48 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/cs/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.38 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/da/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.5 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/de/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.56 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/et/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.64 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/el/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_el.pdf)

français (FR) (13.41 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/fr/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.88 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/hr/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.54 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/is/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.22 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/it/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (85.52 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/lv/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.03 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/lt/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (87.55 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/hu/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (89.7 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/mt/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.11 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/nl/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.48 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/no/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_no.pdf)

polski (PL) (88.91 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/pl/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.45 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/pt/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_pt.pdf)

română (RO) (90.16 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/ro/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (84.81 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/sk/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (13.72 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/sl/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.28 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/fi/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.42 KB - PDF)

**First published:**

21/09/2006

**Last updated:**

21/09/2006

[View](/sv/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine RotaTeq Active substance

- rotavirus serotype G1
- rotavirus serotype G2
- rotavirus serotype G3
- rotavirus serotype G4
- rotavirus serotype P1

International non-proprietary name (INN) or common name rotavirus vaccine, live Therapeutic area (MeSH)

- Immunization
- Rotavirus Infections

Anatomical therapeutic chemical (ATC) code J07BH02

### Pharmacotherapeutic group

- Vaccines
- Viral vaccines

### Therapeutic indication

RotaTeq is indicated for the active immunisation of infants from the age of six weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection.

RotaTeq is to be used on the basis of official recommendations.

## Authorisation details

EMA product number EMEA/H/C/000669 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 27/04/2006 Marketing authorisation issued 26/06/2006 Revision 39

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

RotaTeq : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.38 KB - PDF)

**First published:** 25/04/2025

**Last updated:** 18/12/2025

[View](/en/documents/procedural-steps-after/rotateq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

RotaTeq : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (229.68 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 25/04/2025

[View](/en/documents/procedural-steps-after/rotateq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

RotaTeq-H-C-000669-P46-046 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/367688/2021

English (EN) (407.29 KB - PDF)

**First published:** 09/09/2021

[View](/en/documents/variation-report/rotateq-h-c-000669-p46-046-epar-assessment-report_en.pdf)

RotaTeq-H-C-PSUSA-00002666-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(

Reference Number: EMA/321811/2020

English (EN) (102.47 KB - PDF)

**First published:** 14/09/2020

[View](/en/documents/scientific-conclusion/rotateq-h-c-psusa-00002666-201911-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

RotaTeq-H-C-669-P46-0045 : EPAR - Assessment Report

Adopted

Reference Number: EMA/412818/2016

English (EN) (1.46 MB - PDF)

**First published:** 14/06/2016

**Last updated:** 14/06/2016

[View](/en/documents/variation-report/rotateq-h-c-669-p46-0045-epar-assessment-report_en.pdf)

RotaTeq-H-C-669-P46-0044 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/180644/2016

English (EN) (1.56 MB - PDF)

**First published:** 19/04/2016

**Last updated:** 19/04/2016

[View](/en/documents/variation-report/rotateq-h-c-669-p46-0044-epar-assessment-report_en.pdf)

RotaTeq-H-C-669-P46-0037 : EPAR - Assessment Report

Adopted

Reference Number: EMA/715446/2014

English (EN) (161.01 KB - PDF)

**First published:** 20/11/2014

**Last updated:** 20/11/2014

[View](/en/documents/variation-report/rotateq-h-c-669-p46-0037-epar-assessment-report_en.pdf)

RotaTeq-H-C-669-P46-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/73981/2014

English (EN) (157.33 KB - PDF)

**First published:** 20/11/2014

**Last updated:** 20/11/2014

[View](/en/documents/variation-report/rotateq-h-c-669-p46-0029-epar-assessment-report_en.pdf)

RotaTeq-H-C-669-A20-0025 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/CHMP/797399/2010

English (EN) (113.43 KB - PDF)

**First published:** 17/04/2013

**Last updated:** 17/04/2013

[View](/en/documents/variation-report/rotateq-h-c-669-a20-0025-epar-assessment-report-article-20_en.pdf)

RotaTeq-H-C-669-II-0031: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/251107/2012

English (EN) (222.8 KB - PDF)

**First published:** 12/07/2012

**Last updated:** 12/07/2012

[View](/en/documents/variation-report/rotateq-h-c-669-ii-0031-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for RotaTeq

Adopted

Reference Number: EMA/CHMP/49745/2012

English (EN) (42.94 KB - PDF)

**First published:** 20/01/2012

**Last updated:** 20/01/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rotateq_en.pdf)

## Initial marketing authorisation documents

RotaTeq : EPAR - Scientific Discussion

English (EN) (495.1 KB - PDF)

**First published:** 21/09/2006

**Last updated:** 21/09/2006

[View](/en/documents/scientific-discussion/rotateq-epar-scientific-discussion_en.pdf)

RotaTeq : EPAR - Procedural steps taken before authorisation

English (EN) (39.89 KB - PDF)

**First published:** 21/09/2006

**Last updated:** 21/09/2006

[View](/en/documents/procedural-steps/rotateq-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on RotaTeq

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 January 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-january-2012) 20/01/2012

[European Medicines Agency confirms positive benefit-risk balance of RotaTeq](/en/news/european-medicines-agency-confirms-positive-benefit-risk-balance-rotateq) 23/09/2010

#### More information on RotaTeq

- [EMEA000967-PIP01-10-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea000967-pip01-10-m01)
- [Observational study to assess effectiveness of ROTATEQ® against acute gastroenteritis (AGE) due to rotavirus (regardless of type) and by type in China - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000734)
- [Effectiveness of ROTATEQ® when administered with intervals greater than 10 weeks between doses in Chinese children: an observational study of V260-077 study participants with longer dosing interval (V260-080) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000730)
- [Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in China (V260-077) - post-authorisation study](https://catalogues.ema.europa.eu/study/48721)
- [201889 - Planned analyses related to the Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception following Rotarix introduction into the Instituto Mexicano del Seguro Social (IMSS) in Mexico. - post-authorisation study](https://catalogues.ema.europa.eu/study/31674)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 18/12/2025

## Share this page

[Back to top](#main-content)